| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015216 |
| Receipt No. | R000016418 |
| Official scientific title of the study | Effect of treatment with compression gloves and compression stockings to prevent paclitaxel-induced peripheral. neuropathy |
| Date of disclosure of the study information | 2014/09/21 |
| Last modified on | 2016/09/05 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of treatment with compression gloves and compression stockings to prevent paclitaxel-induced peripheral. neuropathy | |
| Title of the study (Brief title) | gloves and stockings to prevent paclitaxel-induced peripheral neuropathy | |
| Region |
|
|
| Condition | ||
| Condition | non small cell lung cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | By wearing compression gloves and compression stockings at start of chemotherapy, we analyze period to occurrence, frequency, and extent of peripheral neuropathy. We also evaluate relationship among peripheral neuropathy and effect and dose intensity of chemotherapy. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The incidence of peripheral neuropathy in the third cycle before starting |
| Key secondary outcomes | 1) period to development of neurotoxicity (grade 2 or more)
2)proportion of cases who experience contra-lateral neuropathy previous to intervention side. 3) grade of neuropathy 4)relationship among proportion of neuropathy and proportion of completion and effect of chemotherapy. 5) safety of compression gloves and compression stockings. |
| Base | |
| Study type | |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | May26,2014-May31,2015 | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) planning to treat with paclitaxel and nob-paclitaxel.
2) 20 years old or more 3) no neuropahty before enrollment 4) controlled diabetes mellitus (DM) or no DM 5) no significant skin disorder of extremities |
|||
| Key exclusion criteria | 1) any grade of neurotoxicity
2) no ability to express toxicity 3) significant skin disorder of extremites 4) symptomatic brain metastasis |
|||
| Target sample size | 18 | |||
| Research contact person | |
| Name of lead principal investigator | Makoto Maemondo |
| Organization | Miyagi Cancer Center |
| Division name | respiratory medicine |
| Address | 47-1 Nodayama Shiote aza Medeshima Natorishi Miyagi |
| TEL | 022-384-3151 |
| maemondo-ma693@niyagi-pho.jp | |
| Public contact | |
| Name of contact person | Makoto Maemondo |
| Organization | Miyagi Cancer Center |
| Division name | respiratory medicine |
| Address | 47-1 Nodayama Shiote aza Medeshima Natorishi Miyagi |
| TEL | 022-384-3151 |
| Homepage URL | |
| maemondo-ma693@niyagi-pho.jp | |
| Sponsor | |
| Institute | Miyagi Cancer center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Miyagi Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016418 |